Lantern Pharma/$LTRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantern Pharma
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Ticker
$LTRN
Sector
Primary listing
Employees
16
Headquarters
Website
Lantern Pharma Metrics
BasicAdvanced
$34m
-
-$1.44
2.33
-
Price and volume
Market cap
$34m
Beta
2.33
52-week high
$5.74
52-week low
$1.11
Average daily volume
142k
Financial strength
Current ratio
1.868
Quick ratio
1.682
Total debt to equity
1.714
Profitability
EBITDA (TTM)
-16.593
Management effectiveness
Return on assets (TTM)
-73.31%
Return on equity (TTM)
-157.37%
Valuation
Price to book
8.59
Price to tangible book (TTM)
8.59
Price to free cash flow (TTM)
-1.922
Free cash flow yield (TTM)
-52.04%
Free cash flow per share (TTM)
-1.369
Growth
Earnings per share change (TTM)
-21.71%
3-year earnings per share growth (CAGR)
3.81%
Lantern Pharma News
AllArticlesVideos
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
Business Wire·6 days ago
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Business Wire·2 weeks ago
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.